AI Summary & Key Takeaways
AI InsightCONCLUSION: This study revealed that adalimumab is as effective as methylprednisolone in compressive spinal cord injury in rats.
📌 3 Key Takeaways
Özet
AIM: To evaluate the neuroprotective effects of adalimumab in an experimental spinal cord injury model and compare them with those of the widely-used methylprednisolone. MATERIAL and METHODS: Forty male Wistar rats were divided into as the sham, trauma, adalimumab, methylprednisolone, and adalimumab+methylprednisolone groups. Only Iaminectomy was performed in the sham group. Laminectomy and trauma was performed to the trauma group but no treatment was given. single dose of 40 mg/kg subcutaneous adalimumab was administered after the Iaminectomy and trauma to group 3. single dose of intravenous 30 mg/kg methylprednisolone was administered right after Iaminectomy and trauma to group 4. Single doses of 40 mg/kg adalimumab and 30 mg/kg methylprednisolone were administered together after Iaminectomy and trauma to group 5. Serum malondialdehyde (MDA), TNF-cı, IL-1B and IL—6 levels were measured and sections were obtained for histopathological study at the end of the 7‘h day. RESULTS: MDA, TNF-o, IL—1B and IL—6 levels in serum were significantly decreased in the adalimumab group with clinical and histopathological improvement not less than the methylprednisolone group. The serum MDA levels were similar when the two drugs were given together or separately but there was statistically quite significant decrease in TNF-a, IL-1B and IL—6 levels with concurrent use. Statistically significantly better results were obtained on histopathological evaluation with the use of both drugs together. CONCLUSION: This study revealed that adalimumab is as effective as methylprednisolone in compressive spinal cord injury in rats.